Deutsche Bank analyst Pito Chickering raised the firm’s price target on Penumbra (PEN) to $376 from $325 and keeps a Buy rating on the shares after hosting a key opinion leader meeting with investors. The analyst came away with incremental confidence in the mechanical thrombectomy market’s mid to long-term growth outlook across venous thromboembolism and arterial. The firm continues to see both leading mechanical thrombectomy systems from Penumbra and Inari Medical (NARI) as well positioned to benefit from increased disease awareness and higher referral treatment rates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PEN:
- Penumbra price target raised to $325 from $297 at Deutsche Bank
- Penumbra price target raised to $320 from $291 at Wells Fargo
- Penumbra price target raised to $303 from $289 at RBC Capital
- Penumbra price target raised to $312 from $301 at BTIG
- Penumbra price target raised to $300 from $285 at Piper Sandler